China Pharma Holdings (CPHI) FCF Margin (2010 - 2026)

China Pharma Holdings has reported FCF Margin for 17 years, with the latest figure at 5.62% in Q1 2026.

• For the quarter ending Q1 2026, FCF Margin rose 600.0% year-over-year to 5.62%; the trailing twelve-month figure through Mar 2026 stood at 4.15% (up 329.0% YoY), and the FY2025 full-year result was 2.15%, up 1196.0% from the prior year.
• FCF Margin for Q1 2026 stood at 5.62%, down from 12.36% in the prior quarter.
• The five-year high for FCF Margin was 52.11% in Q3 2023, with the low at 72.04% in Q1 2023.
• Historically, FCF Margin has averaged 8.44% across 5 years, with a median of 5.62% in 2026.
• Annual changes were most pronounced in 2022 — FCF Margin plunged 5955 bps — and 2023, when it soared 5381 bps.
• China Pharma Holdings' FCF Margin stood at 20.95% in 2022, then slumped by 106 bps to 1.25% in 2023, then jumped by 2071 bps to 24.62% in 2024, then tumbled by 50 bps to 12.36% in 2025, then plunged by 145 bps to 5.62% in 2026.
• The last three FCF Margin figures came in at 5.62% (Q1 2026), 12.36% (Q4 2025), and 31.42% (Q3 2025), per Business Quant data.